Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Part of $10.05M registered direct offering at $1.455/share; also acquired 687,285 warrants at $1.33 strike. Post-buy holding 2,043,661 shares. Current price $0.875 (−39.9% from buy price). CRDF developing onvansertib (PLK1 inhibitor) for RAS-mutated CRC Phase 2.
Open-market accumulation across July 13–15 at weighted avg ~$3.55/share. Tang Capital group total stake now 6,913,329 shares (~8.2%). Current price $3.50 (−1.4% from avg buy). FULC developing losmapimod for FSHD.
AIThe day in insider buying
SEC Form 4 Insider Scan — July 17, 2026
Scanned the last 24 hours of EDGAR Form 4 filings. 2 qualifying buys (≥ $250K, transaction type P) totalling $1.9M.
Headline filings
CRDF — Gary W. Pace (Director) bought 687,285 shares ≈ $1.0M at $1.455 avg; now $0.87 (−39.9% since buy). Part of Cardiff Oncology's $10.05M registered direct offering announced July 15, 2026; also acquired 687,285 warrants at $1.33 exercise price. Post-buy holding: 2,043,661 shares. (filing)
FULC — Kevin Tang / Tang Capital Partners (10% Owner) bought 249,946 shares ≈ $887K at ~$3.55 weighted avg across July 13–15; now $3.50 (−1.4% since buy). Tang Capital group total stake now 6,913,329 shares (~8.2%). Steady accumulation play. (filing)
Notes
Both qualifying buys are in clinical-stage biotechs. CRDF (Cardiff Oncology) is advancing onvansertib, a PLK1 inhibitor, in Phase 2 trials for RAS-mutated colorectal cancer; the director's purchase came alongside a broader fundraise. FULC (Fulcrum Therapeutics) is focused on epigenetic therapies including losmapimod for facioscapulohumeral muscular dystrophy; Tang Capital has been methodically building its stake. The day's buy volume was light overall — most Form 4s filed July 16–17 were small ESPP/plan-driven transactions or sub-$250K purchases by officers at larger companies (FIS director: $57K; ANIX director: $9K). No cluster buys or large-cap executive purchases in this window.
Most-bought stocks, last 30 days
AVO$74.5M · 14 buys, 4 insidersMission Produce, Inc.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.